文献速递乳腺癌

转移性乳腺癌中ESR1突变检测的动力学与决定因素

Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer.
PubMed 文献 · Ann Oncol · 2025-11-17

PADA-1研究纳入1017例HR+/HER2-晚期乳腺癌患者,一线AI联合哌柏西利治疗中动态监测血ESR1突变。基线突变率3.2%,上升突变在6个月后至3年内更常见;更新生存结果支持早期干预改善PFS(HR 0.54)和PFS2(HR 0.35)。

要点

  • 基线bESR1-mut检出率3.2%,辅助AI治疗史和较低BMI与检出率较高相关。
  • 上升突变非线性出现,6个月后至3年内更常见,骨转移、高ER表达等与检出率较高相关。
  • 早期干预bESR1-mut可改善PFS(HR 0.54)和PFS2(HR 0.35)。

核心结论

  • 识别了基线和治疗中bESR1-mut检出的相关因素,有助于筛选可能从ESR1靶向治疗中获益的患者。

研究设计与样本

  • PADA-1为法国83家医院开展的多中心、开放标签、随机对照III期试验,共纳入1017例HR+/HER2-晚期乳腺癌患者。

主要发现

  • 基线bESR1-mut检出率为3.2%。
  • 既往辅助AI治疗(6.8%)和较低BMI与基线bESR1-mut检出率较高独立相关。
  • 高ER表达、骨转移、年轻和LDH升高与上升bESR1-mut检出率较高相关。
  • 更新生存结果:PFS的HR 0.54(95%CI 0.38-0.75),PFS2的HR 0.35(95%CI 0.22-0.54)。

关键数值与推荐

  • 基线bESR1-mut检出率3.2%,既往辅助AI治疗者6.8%。
  • 上升bESR1-mut在6个月后至3年内更常见。
  • 早期干预bESR1-mut的PFS HR 0.54(95%CI 0.38-0.75),PFS2 HR 0.35(95%CI 0.22-0.54)。

临床怎么用

  • 对HR+/HER2-晚期乳腺癌一线AI联合哌柏西利治疗患者,可动态监测bESR1-mut以指导早期干预。
  • 具有辅助AI治疗史、骨转移、年轻、高ER表达或LDH升高等特征者可能更需关注bESR1-mut检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: PADA-1 was the first prospective randomized trial to show that early therapeutic targeting of blood ESR1 mutations (bESR1-mut) with fulvestrant provides significant clinical benefit in patients with estrogen receptor α-positive/human epidermal growth factor receptor 2-negative advanced breast cancer treated with an aromatase inhibitor and palbociclib. Here, we describe the kinetics and determinants of bESR1-mut in the 1017 patients who participated in PADA-1. PATIENTS AND METHODS: PADA-1 was an open-label, randomized, controlled, phase III trial conducted at 83 hospitals in France. Patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer were recruited and monitored by multiplex droplet digital PCR for rising bESR1-mut during first-line treatment with aromatase inhibitor and palbociclib, after one cycle and then every two cycles. Patients with newly present or increased bESR1-mut in circulating tumor DNA and no synchronous disease progression were randomly assigned to continue with the same therapy or to switch to fulvestrant and palbociclib. RESULTS: Baseline bESR1-mut was detected in 3.2% of patients. Prior adjuvant treatment with aromatase inhibitor (6.8%) and lower body mass index were independently associated with a higher detection rate of bESR1-mut at baseline. Through real-time analysis of >12 500 blood samples, we observed that detection of rising bESR1-mut was not linear over time, occurring more frequently after 6 months and before 3 years of treatment. We found that high estrogen receptor expression, the presence of bone metastases, younger age, and lactate dehydrogenase elevation were associated with a higher rate of rising bESR1-mut detection. Finally, updated survival results of PADA-1 substantiate the clinical benefit of intercepting bESR1-mut emergence before clinical progression, with improved progression-free survival (PFS), hazard ratio 0.54, 95% confidence interval 0.38-0.75, and progression-free survival 2, hazard ratio 0.35, 95% confidence interval 0.22-0.54. CONCLUSION: We identified factors associated with the detection of bESR1-mut at baseline and during treatment that could help identify patients who may benefit from ESR1-targeted therapies.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Cabel L, Berger F, Bachelot T, et al. Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer. Ann Oncol. 2025. PMID: 41260263. doi:10.1016/j.annonc.2025.11.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。